Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02451618 · ClinicalTrials.gov registry record
Novel Epidermal Recording and Detection of Seizures
A clinical trial, sponsored by Sharp HealthCare.
- Terminated
- Registry status
- 13
- Enrollment target
NCT02451618: Clinical Trial study, sponsored by Sharp HealthCare.
NCT02451618 is a clinical trial that was terminated before completion, run by Sharp HealthCare. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02451618 was terminated before completion, sponsored by Sharp HealthCare.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
For any newborn that exhibits possible seizure activity or has altered mental status of unknown etiology, continuous bedside EEG recording is the standard of care to detect subclinical seizure activity. The experimental aspect of this study will be the application of test electrodes (EES or EKG) to evaluate if the electrodes can be used to produce a continuous bedside recording of brain activity in the same manner as an EEG recording, while ideally producing less irritation of newborn skin than conventional EEG electrodes.
Primary Outcome
Seizures detected by study electrodes will be compared to seizures detected on conventional EEG recording.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-01-27 |
Why NCT02451618 stopped before completion
NCT02451618 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02451618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02451618 about?
NCT02451618 is a clinical study titled "Novel Epidermal Recording and Detection of Seizures". For any newborn that exhibits possible seizure activity or has altered mental status of unknown etiology, continuous bedside EEG recording is the standard of care to detect subclinical seizure activity. The experimental aspect of this study will be the application of test electrodes (EES or EKG) to ...
What is the current status of trial NCT02451618?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2015-01-27.
Who is sponsoring clinical trial NCT02451618?
This trial is sponsored by Sharp HealthCare, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI